Pituitary Apoplexy

Published on 14/03/2015 by admin

Filed under Emergency Medicine

Last modified 14/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1457 times

170 Pituitary Apoplexy

Epidemiology

Pituitary adenomas are common, with a prevalence of 3% to 27% in various autopsy series. They are rarely diagnosed in life, with a reported incidence of 4 per 100,000 in a Finnish population and a prevalence of 77 per 100,000 in a British one.1,2 Apoplexy occurs in a minority of such lesions and can occasionally be seen with normal glands. Because of the relative rarity of this condition, pituitary apoplexy may be confused with more common entities such as subarachnoid hemorrhage. Delay in diagnosis and treatment may lead to blindness, permanent cranial nerve palsies, or death.3,4

Pathophysiology

The two lobes of the pituitary gland sit within an enclosed space known as the sella turcica. Blood supply to this gland is one of the richest of all mammalian tissues.

The anterior lobe receives the portal hypophyseal vessel from the hypothalamus. Differentiated cells in the anterior lobe secrete specific hormones, including growth hormone (GH), adrenocorticotropic hormone (ACTH), prolactin (PRL), thyroid-stimulating hormone (TSH), and gonadotropins: luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

The posterior lobe is an extension of the hypothalamus and secretes two hormones: antidiuretic hormone (or arginine vasopressin) and oxytocin. The pituitary stalk and the portal vessel pass through a small diaphragm that separates the sella turcica from the middle fossa. This anatomic arrangement places the pituitary at risk for infarction or hemorrhage when a mass increases pressure in the sella or compresses the stalk and vessels. Higher intrasellar pressures are associated with poor outcomes.

Pituitary tumors are common and many are asymptomatic. They are classified by size (microadenoma, <10 mm; macroadenoma, >10 mm) and by the hormone produced. Of tumors that cause clinical symptoms, the most commonly secreted hormones are PRL, which leads to hypogonadism; GH, which promotes acromegaly; and ACTH, a cause of Cushing disease.

Tumors involved in apoplexy are typically nonfunctional and unsuspected macroadenomas. In patients undergoing an endocrine stimulation test for hypogonadism, hypothyroidism, or adrenal insufficiency, apoplexy may occasionally develop secondary to stimulation of a macroadenoma. Treatment of a pituitary tumor can also precipitate apoplexy, particularly in cases of surgery, irradiation, or bromocriptine administration. Other reported risk factors include pregnancy (Sheehan syndrome), head trauma, recent cardiac surgery, anticoagulation, hypertension, diabetic ketoacidosis, and ovarian stimulation medications.5

Most patients with pituitary apoplexy have no identifiable risk factor. Apoplexy may occur in normal glands.